newsfilter
← Latest News
Business Wire·

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First